In Q1 2024, Tang Capital Management held 71 positions worth $777.9M. They initiated 17 new positions and exited 48. Their largest holding was TARS ($82.0M). Portfolio value grew +7.6% versus the prior quarter.
Frequently asked questions
What stocks did Tang Capital Management own in Q1 2024?
Tang Capital Management held 71 biotech stocks in their 13F portfolio in Q1 2024. Their top positions include TARS, EOLS, KALV, ANAB, MIRM. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Tang Capital Management's portfolio worth in Q1 2024?
Tang Capital Management's tracked biotech portfolio was worth $777.9M across 71 positions, with total assets under management of approximately $2B. Portfolio values are based on 13F filings with the SEC.
What did Tang Capital Management buy in Q1 2024?
Tang Capital Management initiated 17 new positions in Q1 2024, including INBX, IMNM, APLD, LENZ, ANIP and 12 more. They also increased 14 existing positions.
What did Tang Capital Management sell in Q1 2024?
Tang Capital Management fully exited 48 positions in Q1 2024, including SCYX, RXDX, ITOS, TIL, FHN-PH and 43 more. They also trimmed 26 existing positions.
Is Tang Capital Management a biotech fund?
Event-driven biotech specialist known for concentrated bets around clinical catalysts, M&A situations, and activist campaigns. Deep industry relationships and willingness to engage publicly make the fund a closely watched market signal.
Want AI analysis, insider signals, and catalyst overlays for Tang Capital Management?
View latest Tang Capital Management portfolio →